296 related articles for article (PubMed ID: 31936239)
1. Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer.
Jin W
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31936239
[TBL] [Abstract][Full Text] [Related]
2. Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling.
Fan Y; Zhang B; Du X; Wang B; Yan Q; Guo L; Yao W
Curr Cancer Drug Targets; 2024; 24(3):271-287. PubMed ID: 37670705
[TBL] [Abstract][Full Text] [Related]
3. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer.
Kim MS; Jeong J; Seo J; Kim HS; Kim SJ; Jin W
Sci Rep; 2016 Sep; 6():33899. PubMed ID: 27654855
[TBL] [Abstract][Full Text] [Related]
5. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting TRK Proteins in Clinical Cancer Therapy.
Lange AM; Lo HW
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282
[TBL] [Abstract][Full Text] [Related]
7. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
8. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cocco E; Lee JE; Kannan S; Schram AM; Won HH; Shifman S; Kulick A; Baldino L; Toska E; Arruabarrena-Aristorena A; Kittane S; Wu F; Cai Y; Arena S; Mussolin B; Kannan R; Vasan N; Gorelick AN; Berger MF; Novoplansky O; Jagadeeshan S; Liao Y; Rix U; Misale S; Taylor BS; Bardelli A; Hechtman JF; Hyman DM; Elkabets M; de Stanchina E; Verma CS; Ventura A; Drilon A; Scaltriti M
Cancer Discov; 2021 Jan; 11(1):126-141. PubMed ID: 33004339
[TBL] [Abstract][Full Text] [Related]
9. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
[TBL] [Abstract][Full Text] [Related]
10. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
[TBL] [Abstract][Full Text] [Related]
11. Alterations in tyrosine kinase receptor (Trk) expression induced by insulin-like growth factor-1 in cultured dorsal root ganglion neurons.
Li H; Zhang P; Fu G; Li J; Liu H; Li Z
Brain Res Bull; 2013 Jan; 90():25-34. PubMed ID: 23022575
[TBL] [Abstract][Full Text] [Related]
12. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
[TBL] [Abstract][Full Text] [Related]
13. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
14. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
[TBL] [Abstract][Full Text] [Related]
15. TrkC promotes colorectal cancer growth and metastasis.
Kim MS; Suh KW; Hong S; Jin W
Oncotarget; 2017 Jun; 8(25):41319-41333. PubMed ID: 28455963
[TBL] [Abstract][Full Text] [Related]
16. TrkC plays an essential role in breast tumor growth and metastasis.
Jin W; Kim GM; Kim MS; Lim MH; Yun C; Jeong J; Nam JS; Kim SJ
Carcinogenesis; 2010 Nov; 31(11):1939-47. PubMed ID: 20802235
[TBL] [Abstract][Full Text] [Related]
17. Neurotrophin Trk Receptors: New Targets for Cancer Therapy.
Meldolesi J
Rev Physiol Biochem Pharmacol; 2018; 174():67-79. PubMed ID: 28884193
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of TrkC (NTRK3) in human soft tissue tumours.
Hisaoka M; Sheng WQ; Tanaka A; Hashimoto H
J Pathol; 2002 Aug; 197(5):661-7. PubMed ID: 12210087
[TBL] [Abstract][Full Text] [Related]
19. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z; Wang J; Wang Y; Xiang S; Song X; Tu Z; Zhou Y; Zhang ZM; Zhang Z; Ding K; Lu X
J Med Chem; 2022 Apr; 65(8):6325-6337. PubMed ID: 35426680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
